Nonalcoholic fatty liver in patients with Laron syndrome and GH gene deletion - preliminary report

Growth Horm IGF Res. 2008 Oct;18(5):434-438. doi: 10.1016/j.ghir.2008.03.003. Epub 2008 May 6.

Abstract

Background: There is little information on the relationship between growth hormone/insulin-like growth factor-I (GH/IGF-I) deficiency or IGF-I treatment on nonalcoholic fatty liver disease (NAFLD) a disorder linked to obesity and insulin resistance.

Objective: To find out whether the markedly obese patients with Laron syndrome (LS) and GH gene deletion have fatty livers.

Subjects: We studied 11 untreated adult patients with LS (5M, 6F), five girls with LS treated by IGF-I and five adult patients with GH gene deletion (3M, 3F), four previously treated by hGH in childhood.

Methods: Fatty liver was quantitatively evaluated by ultrasonography using a phase array US system (HITACHI 6500, Japan). Body adiposity was determined by DEXA, and insulin resistance was estimated by HOMA-IR using the fasting serum glucose and insulin values.

Results: Six out of 11 adult patients with LS, two out of the five IGF-I treated girls with LS and three out of five adult hGH gene deletion patients were found to have NAFLD (nonalcoholic fatty liver disease).

Conclusion: NAFLD is a frequent complication in untreated and treated congenital IGF-I deficiency. No correlation between NAFLD and age, sex, degree of obesity, blood lipids, or degree of insulin resistance was observed.

MeSH terms

  • Adult
  • Fatty Liver / diagnostic imaging
  • Fatty Liver / etiology*
  • Fatty Liver / metabolism
  • Female
  • Gene Deletion*
  • Human Growth Hormone / genetics*
  • Human Growth Hormone / metabolism
  • Humans
  • Insulin Resistance
  • Insulin-Like Growth Factor I / deficiency
  • Laron Syndrome / complications*
  • Laron Syndrome / metabolism
  • Male
  • Middle Aged
  • Ultrasonography

Substances

  • Human Growth Hormone
  • Insulin-Like Growth Factor I